A carregar...
4-1BB agonism: adding the accelerator to cancer immunotherapy
The success of checkpoint inhibitors has validated immunomodulatory agents as a valuable class of anticancer therapeutics. A promising co-stimulatory immunologic target is 4-1BB, or CD137, a member of the tumor necrosis factor receptor superfamily. Ligation of 4-1BB induces an activating signal in C...
Na minha lista:
| Publicado no: | Cancer Immunol Immunother |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5035667/ https://ncbi.nlm.nih.gov/pubmed/27034234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1829-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|